Moin Makda Presented ThalSaarthi with Attempt to Solve HbA2 Borderline Specific Problem
Moin Makda, AI Developer at Fortis Memorial Research Institute, posted on LinkedIn:
“”Is it normal or is it trait?”
A question asked thousands of times daily across India. HbA2 borderline. Traditional algorithms say inconclusive, patient waits days for expert opinion.
At Haematocon 2025, I presented ThalSaarthi with our attempt to solve this specific problem.
Every 35 minutes, a child is born with thalassemia major in India. Over 40 million carriers exist, but 70% of our population lacks access to expert hemoglobinopathy screening. The gap between disease burden and diagnostic capacity is staggering.
We built something different. An AI system that brings expert level hemoglobinopathy interpretation to district hospitals and mobile screening camps where it’s needed most. The goal isn’t to replace hematologists but to extend their reach.
What makes it different:
-> Works completely offline (privacy preserving, no cloud dependency)
-> Resolves the ambiguous, borderline cases that traditional algorithms fail on
-> Built specifically for resource constrained environments
The technical innovation: combining rule-based clinical logic with RAG + AI reasoning. Fast for clear cases. Intelligent for complex ones.
This isn’t about technology for technology’s sake. It’s about health equity. It’s about reaching the 70% who currently have less access. It’s about prevention at scale.
Deeply grateful to my mentors and team: Dr. Rahul Bhargava, Shrinidhi Nathany Swarsat K. Nath Dr. Kamlesh Prajapati
When expertise is scarce, intelligence must scale.”

Stay updated with Hemostasis Today.
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025
-
Mar 12, 2026, 16:36Giordano Botta: From the ‘Power of Zero’ to a Precise Understanding of Cardiovascular Risk
-
Mar 12, 2026, 16:31Katie Baca-Motes: Incorporating Menstrual Cycle and Hormonal Rhythms Into Clinical Research
-
Mar 12, 2026, 16:22Augustina Isioma Ikusemoro: Quality Indicators in Processed Blood Components
-
Mar 12, 2026, 16:20Aryabhatta Sadhu: The Full Spectrum of Transplant Immunology and Clinical Care
-
Mar 12, 2026, 16:17Megan Adediran: Building Pathways to Sustainable Care for People With Bleeding Disorders in Nigeria
-
Mar 12, 2026, 16:09Rob Mac Sweeney: Hemodynamic Failure During Sepsis